The company’s sales revenue dropped 12% on the year, to RON340 million, it said in its preliminary earnings report.
It said sales on international markets amounted to RON158.27 million, 4% higher compared with 2019, and exports accounted for 46% of sales revenue in 2020, from 39% in 2019.
The company’s evolution was in line with that of the pharmaceutical market overall, as the value of its sales amounted to RON318.6 million, down 5.2% on the year. By volume, Antibiotice posted a 15.9% drop from 31 million boxes in 2019 to 26 million boxes in 2020.
In terms of value, the hospital segment was most affected in the context of the pandemic, posting a 10.3% decline, to RON75.9 million in 2020. Quantities sold in hospitals declined 27.8%, to 1.3 million boxes.
Antibiotice Iasi had total revenues of RON380.39 million and expenses amounted to 352.06 million.
Antibiotice Iasi is 53% owned by the Romanian state and regional investment fund SIF Oltenia owns 18.9%.